DK 15-10
Alternative Names: DK 1510Latest Information Update: 25 Sep 2023
At a glance
- Originator Deka Biosciences
- Class Antineoplastics; Immunoglobulin Fv fragments; Immunotherapies; Interleukins; Recombinant fusion proteins
- Mechanism of Action Interleukin 10 replacements; Interleukin 15 replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Research Bladder cancer; Colorectal cancer; Head and neck cancer; Lung cancer; Pancreatic cancer; Renal cancer; Skin cancer
Most Recent Events
- 25 Sep 2023 DK 15-10 is available for licensing as of 25 Sep 2023. https://www.dekabiosciences.com/our-science/ (Deka Biosciences pipeline, September 2023)
- 18 Sep 2023 Early research in Bladder cancer in USA (SC), prior to September 2023 (Deka Biosciences pipeline, September 2023)
- 18 Sep 2023 Early research in Colorectal cancer in USA (SC), prior to September 2023 (Deka Biosciences pipeline, September 2023)